Ignite Creation Date:
2025-12-24 @ 2:16 PM
Ignite Modification Date:
2026-02-02 @ 7:28 AM
Study NCT ID:
NCT04161495
Status:
COMPLETED
Last Update Posted:
2025-09-17
First Post:
2019-11-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Sponsor:
Bioverativ, a Sanofi company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EFC16293
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None